Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
Crossref DOI link: https://doi.org/10.1007/s10637-017-0479-3
Published Online: 2017-07-05
Published Print: 2017-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Infante, Jeffrey R.
Cohen, Roger B.
Kim, Kevin B.
Burris, Howard A. III
Curt, Gregory
Emeribe, Ugochi
Clemett, Delyth
Tomkinson, Helen K.
LoRusso, Patricia M.
Text and Data Mining valid from 2017-07-05
Version of Record valid from 2017-07-05
Article History
First Online: 5 July 2017